Medicare Enrolled
Dr. Jared Knol, MD
Medical Oncology · Grand Rapids, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Knol from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Knol?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Knol
Dr. Jared Knol is a medical oncology specialist in Grand Rapids, MI, with 18 years of NPI registration. Based on federal Medicare data, Dr. Knol performed 20,479 Medicare services across 1,450 unique beneficiaries.
Between the years covered by Open Payments, Dr. Knol received a total of $1,326 from 24 pharmaceutical and/or device companies across 51 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Knol is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 18% volume in MI
$1,326 industry payments
Medicare Practice Summary
Medicare Utilization ↗20,479
Medicare services
Top 18% in MI for medical oncology
1,450
Unique beneficiaries
$24
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,138 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 7,800 | $43 | $80 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
5,400 | $0 | $3 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,520 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 830 | $1 | $35 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
589 | $2 | $4 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
456 | $8 | $15 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
357 | $8 | $26 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
347 | $10 | $35 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
288 | $11 | $34 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
282 | $92 | $189 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
238 | $66 | $133 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
231 | $92 | $292 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 228 | $134 | $354 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
179 | $2 | $8 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
168 | $6 | $25 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
155 | $2 | $4 |
| PSA test (prostate cancer screening) | 119 | $18 | $63 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
117 | $22 | $86 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
111 | $10 | $38 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
80 | $9 | $26 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
79 | $23 | $72 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
77 | $92 | $180 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
72 | $93 | $220 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
67 | $80 | $70 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
63 | $52 | $123 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
59 | $21 | $47 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
55 | $16 | $57 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
55 | $21 | $66 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
52 | $25 | $83 |
| Total testosterone level test A blood test that measures the total amount of testosterone in your body. This hormone is important for various bodily functions in both men and women. |
49 | $25 | $88 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
48 | $7 | $23 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
44 | $1 | $2 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
42 | $44 | $151 |
| Blood or blood product transfusion The administration of whole blood or specific blood components into a patient's bloodstream. |
34 | $27 | $95 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
33 | $47 | $142 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
33 | $133 | $264 |
| New patient office visit, complex (60-74 min) | 24 | $160 | $324 |
| Hepatitis B core antibody test A blood test that measures the level of antibodies to the hepatitis B core antigen. This test helps determine if a person has been infected with the hepatitis B virus. |
16 | $12 | $30 |
| Hepatitis B surface antigen test A blood test that uses an immunoassay technique to detect the presence of the hepatitis B surface antigen. This test identifies whether the hepatitis B virus is currently present in the body. |
16 | $10 | $26 |
| Hepatitis B surface antibody test A blood test that measures the level of antibodies against the hepatitis B surface antigen. This test is used to check for immunity to hepatitis B or to verify the effectiveness of the hepatitis B vaccine. |
15 | $11 | $27 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
14 | $13 | $46 |
| Iron level test | 14 | $6 | $22 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
12 | $116 | $285 |
| Vitamin B-12 level test A blood test that measures the amount of vitamin B-12 in your body. |
11 | $15 | $51 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.3% high complexity
84.3% medium
12.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,326
Total received (2018-2024)
Avg $189/year across 7 years
Bottom 39% in MI for medical oncology
24
Companies
51
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,228 (92.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$97 (7.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$343
2023
$155
2022
$214
2021
$59
2020
$12
2019
$297
2018
$245
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$56
Merck Sharp & Dohme LLC
$47
SpringWorks Therapeutics, Inc.
$46
PFIZER INC.
$33
Astellas Pharma US Inc
$28
Novartis Pharmaceuticals Corporation
$27
ABBVIE INC.
$25
Amneal Pharmaceuticals LLC
$22
Daiichi Sankyo Inc.
$21
Kite Pharma, Inc.
$19
Celgene Corporation
$19
Top 3 companies account for 43.5% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$208
E.R. Squibb & Sons, L.L.C.
$139
PFIZER INC.
$131
AstraZeneca Pharmaceuticals LP
$113
Foundation Medicine, Inc.
$112
Pharmacyclics LLC, an AbbVie Company
$85
Merck Sharp & Dohme LLC
$64
Novartis Pharmaceuticals Corporation
$60
Array BioPharma Inc.
$60
SpringWorks Therapeutics, Inc.
$46
Aadi Bioscience, Inc.
$38
Astellas Pharma US Inc
$28
ABBVIE INC.
$25
EISAI INC.
$24
Myovant Sciences Inc.
$24
Lilly USA, LLC
$24
Amneal Pharmaceuticals LLC
$22
Daiichi Sankyo Inc.
$21
Amgen Inc.
$20
Kite Pharma, Inc.
$19
Celgene Corporation
$19
JAZZ PHARMACEUTICALS INC.
$18
Genentech USA, Inc.
$13
Karyopharm Therapeutics Inc.
$12
Top 3 companies account for 36.1% of all-time payments
Associated products mentioned in payments ›
AVASTIN · Alecensa · Braftovi · Dayvigo · Enhertu · FOUNDATIONONE · Fyarro · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · KEYTRUDA · LUTATHERA · MVASI · OGSIVEO · OPDIVO · ORGOVYX · PLUVICTO · REBLOZYL · TAGRISSO · Trodelvy · VENCLEXTA · VERZENIO · VYXEOS · XPOVIO · Xospata · Yescarta · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
11
Per 100K population
1.7
County median income
$80,390
Nearest hospital
SPECTRUM HEALTH
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Knol is a mixed practice specialist, with above-average Medicare volume (top 18% in MI), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Knol experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Knol performed 7,800 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Knol receive payments from pharmaceutical companies?
Yes. Dr. Knol received a total of $1,326 from 24 companies across 51 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Knol's costs compare to other medical oncologists in Grand Rapids?
Dr. Knol's average Medicare payment per service is $24. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Knol) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Grand Rapids
Browse medical oncologists in Grand Rapids ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in MI
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in MI
Which MI medical oncologists receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology